MSC-Based Cell Therapy for COVID-19-Associated ARDS and Classical ARDS : Comparative Perspectives
(2023) In Current Stem Cell Reports- Abstract
Purpose of Review: Despite no general conclusions regarding the therapeutic effect of MSCs on virus-induced acute lung injury in pre-clinical studies, a significant number of clinical trials using MSC-based treatment for COVID-19-associated ARDS were initiated during the global pandemic. Here, we aimed to discuss differences and similarities in clinical trials using MSC-based treatments for classical ARDS and COVID-19-associated ARDS and to raise some future perspectives. Recent Findings: Several pre-clinical studies have demonstrated that MSC treatment may not be a good treatment option for virus infections because MSCs themselves are susceptible to the virus. However, MSCs lack expression of the angiotensin-converting enzyme 2 (ACE2)... (More)
Purpose of Review: Despite no general conclusions regarding the therapeutic effect of MSCs on virus-induced acute lung injury in pre-clinical studies, a significant number of clinical trials using MSC-based treatment for COVID-19-associated ARDS were initiated during the global pandemic. Here, we aimed to discuss differences and similarities in clinical trials using MSC-based treatments for classical ARDS and COVID-19-associated ARDS and to raise some future perspectives. Recent Findings: Several pre-clinical studies have demonstrated that MSC treatment may not be a good treatment option for virus infections because MSCs themselves are susceptible to the virus. However, MSCs lack expression of the angiotensin-converting enzyme 2 (ACE2) receptor, suggesting that MSCs are not likely to be infected by the COVID-19 virus. Interestingly, recent meta-analyses demonstrated that an improved survival rate in patients with COVID-19-associated ARDS treated with MSCs was obtained in 24 out of 26 completed clinical trials. Summary: This review provides comparative perspectives on MSC-based therapy for COVID-19-associated ARDS and classical ARDS.
(Less)
- author
- Weiss, Daniel J. and Rolandsson Enes, Sara LU
- organization
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- epub
- subject
- keywords
- Acute respiratory distress syndrome, Cell therapy, COVID-19, Lung, Mesenchymal stromal cells, MSCs
- in
- Current Stem Cell Reports
- publisher
- Springer
- external identifiers
-
- scopus:85178872663
- ISSN
- 2198-7866
- DOI
- 10.1007/s40778-023-00231-6
- language
- English
- LU publication?
- yes
- id
- b9526742-1c66-4703-a463-45447fec4e2a
- date added to LUP
- 2024-01-11 12:32:36
- date last changed
- 2024-01-11 12:35:01
@article{b9526742-1c66-4703-a463-45447fec4e2a, abstract = {{<p>Purpose of Review: Despite no general conclusions regarding the therapeutic effect of MSCs on virus-induced acute lung injury in pre-clinical studies, a significant number of clinical trials using MSC-based treatment for COVID-19-associated ARDS were initiated during the global pandemic. Here, we aimed to discuss differences and similarities in clinical trials using MSC-based treatments for classical ARDS and COVID-19-associated ARDS and to raise some future perspectives. Recent Findings: Several pre-clinical studies have demonstrated that MSC treatment may not be a good treatment option for virus infections because MSCs themselves are susceptible to the virus. However, MSCs lack expression of the angiotensin-converting enzyme 2 (ACE2) receptor, suggesting that MSCs are not likely to be infected by the COVID-19 virus. Interestingly, recent meta-analyses demonstrated that an improved survival rate in patients with COVID-19-associated ARDS treated with MSCs was obtained in 24 out of 26 completed clinical trials. Summary: This review provides comparative perspectives on MSC-based therapy for COVID-19-associated ARDS and classical ARDS.</p>}}, author = {{Weiss, Daniel J. and Rolandsson Enes, Sara}}, issn = {{2198-7866}}, keywords = {{Acute respiratory distress syndrome; Cell therapy; COVID-19; Lung; Mesenchymal stromal cells; MSCs}}, language = {{eng}}, publisher = {{Springer}}, series = {{Current Stem Cell Reports}}, title = {{MSC-Based Cell Therapy for COVID-19-Associated ARDS and Classical ARDS : Comparative Perspectives}}, url = {{http://dx.doi.org/10.1007/s40778-023-00231-6}}, doi = {{10.1007/s40778-023-00231-6}}, year = {{2023}}, }